Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Background. Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant pr
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2017
|
| In: |
Annals of oncology
Year: 2016, Volume: 28, Issue: 2, Pages: 368-376 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw443 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdw443 Verlag, Volltext: https://academic.oup.com/annonc/article/28/2/368/2669811 
|
| Author Notes: | A.M. Menzies, D.B. Johnson, S. Ramanujam, V.G. Atkinson, A.N.M. Wong, J.J. Park, J.L. McQuade, A.N. Shoushtari, K.K. Tsai, Z. Eroglu, O. Klein, J.C. Hassel, J.A. Sosman, A. Guminski, R.J. Sullivan, A. Ribas, M.S. Carlino, M.A. Davies, S.K. Sandhu, G.V. Long |
| Summary: | Background. Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant pr |
|---|---|
| Item Description: | Published: 29 September 2016 Gesehen am 26.09.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw443 |